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Widening the options for recurrent malaria
The global need for new antimalarial drugs and new 
combinations is enormous and urgent,1,2 but their 
successful delivery needs resilience to overcome the 
barriers imposed by expensive and lengthy clinical 
development plans. Attention is often directed to 
areas such as southeast Asia, where some antimalarial 
combinations are failing but transmission intensities 
are much lower than in sub-Saharan African countries. 
Children in Africa have frequent and life-threatening 
malaria infections as they grow up, and these need to 
be treated safely.
Pyronaridine–artesunate and dihydroartemisinin–
piperaquine are two artemisinin combination therapies 
(ACTs) that exemplify the challenges that arise in the 
pathway towards licensure and wider implementation. 
These two drug combinations have a good track 
record of efficacy3,4 and are approved by the European 
Medicines Agency (EMA). However, their introduction 
into first-line therapies in malaria-endemic countries, 
particularly in sub-Saharan Africa where the global 
malaria problem is worst, has been sporadic and slow. 
Questions about the safety of ACTS (ie, hepatotoxicity 
for pyronaridine–artesunate and cardiotoxicity for 
dihydroartemisinin–piperaquine) might have delayed 
their endorsement by WHO,5 thereby obstructing 
adoption into national malaria-control programmes. 
They are also needed in southeast Asia where other 
antimalarial treatments are no longer effective when 
used in conventional doses.6
Adequate assessment of antimalarial drugs should 
not be restricted to investigating their ability to cure a 
single infection safely, but to rather account for their 
overall efficacy in decreasing the long-term cumulative 
incidence of disease and their prolonged safety when 
used repeatedly. In high-transmission, malaria-endemic 
areas, repeated symptomatic malaria infections are 
common until the acquisition of a degree of immunity 
against the disease. In highly endemic vivax transmission 
areas, relapses caused by hypno zoites frequently 
contribute to repeated clinical episodes of malaria. 
In The Lancet, Issaka Sagara and colleagues from the 
West African Network for Clinical Trials of Antimalarial 
Drugs (WANECAM) provide reassuring results on the 
safety and efficacy of pyronaridine–artesunate and 
dihydroartemisinin–piperaquine in a large, randomised, 
controlled trial undertaken in Mali, Burkina Faso, and 
Guinea.7 For 2 years they followed up a longitudinal 
cohort of 4710 adult and paediatric patients aged 
6 months and older with microscopically confirmed 
Plasmodium spp malaria to assess the safety and efficacy 
of pyronaridine–artesunate and dihydroartemisinin–
piperaquine to treat recurrent malaria versus current 
recommended first-line (re)treatments with artemether–
lumefantrine or artesunate–amodiaquine. All treatments 
were once-daily or twice-daily tablets or granules given 
orally over 3 days at the study centres, and patients were 
followed up as outpatients up to day 42.
The results of this large and complex trial7 confirmed 
the non-inferiority of both pyronaridine–artesunate 
and dihydroartemisinin–piperaquine against the 
comparators for the primary endpoints of (1) 2-year 
malaria incidence rate in the intention-to-treat 
population (pyronaridine–artesunate vs artemether–
lume fantrine [1·77, 95% CI 1·63–1·93 vs 1·87, 
1·72–2·03; rate ratio (RR) 1·05, 95% CI 0·94–1·17] and 
vs artesunate–amodiaquine [1·39, 95% CI 1·22–1·59 vs 
1·35, 1·18–1·54; RR 0·97, 0·87–1·07]; dihydroartemisinin–
piperaquine vs artemether–lumefantrine [1·16, 95% CI 
1·01–1·34 vs 1·42, 1·25–1·62; RR 1·22, 95% CI 1·06–1·41] 
and vs artesunate–amodiaquine [1·35, 1·21–1·51 vs 
1·68, 1·51–1·88; RR 1·25, 1·02–1·50]); and (2) adequate 
clinical and parasitological response in uncomplicated 
malaria across all episodes assessed in the per-protocol 
population on days 28 and 42 (for P falciparum malaria, 
PCR-adjusted adequate clinical and parasitological 
response was greater than 99·5% at day 28 and greater 
than 98·6% at day 42 for all ACTs).
These findings highlight that all four ACTs are 
robust in some of the highest pockets of malaria 
transmission globally and they exemplify the 
cumulative advantages of using drug combinations 
that include partner drugs with longer elimination 
half-lives, such as piperaquine (around 4 weeks 
in dihydroartemisinin–piperaquine) or pyronaridine 
(10–13 days in pyro naridine–artesunate). Indeed, 
the crude effects of dihydroartemisinin–piperaquine 
on the 2-year incidence of malaria compared with 
artemether–lumefantrine or artesunate–amodiaquine 
probably reflect the better long-term and cumulative 
effects of post-treatment prophylaxis with piperaquine 
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in preventing new infections, a finding that has 
implications for the current malaria-elimination 
agenda.8
Additionally, the WANECAM study7 confirmed the 
good tolerability of single and repeated treatments 
of pyronaridine–artesunate and dihydroartemisinin–
piperaquine. For pyronaridine–artesunate, this finding 
ratifies the revision in 20159 of the initial 2012 EMA 
approval,10 which originally limited the treatment 
possibilities both individually (to just once in a lifetime) 
and geographically (to low-endemic settings with 
high risk of artemisinin resistance). The 2015 revision 
has removed all restrictions on repeat dosing, on use 
only in areas of high resistance and low transmission, 
and on requirements for liver function monitoring. 
The results from the WANECAM study7 should enable 
rapid inclusion of pyronaridine–artesunate into WHO’s 
malaria treatment guidelines.5
The WANECAM trial did confirm an increased risk of 
liver transaminitis in some recipients of pyronaridine–
artesunate. However, the absence of any clinical 
implication, the transient nature of the increases in all 
cases, and the absence of an incremental effect in those 
receiving repeated doses are reassuring, and support the 
wider use of pyronaridine–artesunate for the treatment 
of malaria. The safety of pyronaridine–artesunate 
should continue to be monitored, including its use in 
HIV-infected individuals, as this particularly vulnerable 
population was excluded from participating in the 
trial—an important limitation for the generalisation of 
the results. A large study of pyronaridine–artesunate 
in which HIV infection is not an exclusion criterion is 
ongoing (NCT03201770).
The WANECAM trial also shed light on other safety 
concerns, particularly prolongation of the QT interval 
and the consequent increased risk of life-threatening 
arrhythmias. The findings suggested that the incidence of 
QTcF prolongation was higher after dihydroartemisinin–
piperaquine versus artemether–lumefantrine and 
pyronaridine–artesunate, but no differences were noted 
between dihydroartemisinin–piperaquine and artesunate–
amodiaquine. There were no clinical symptoms or 
complications associated with the prolongation, and 
retreatment did not seem to make these findings worse, 
although the numbers studied were small.
Manufacturers recommend that dihydroartemisinin–
piperaquine should be taken under fasting conditions to 
minimise the risks of a food effect that increases plasma 
concentrations of piperaquine and cardiac effects. In the 
WANECAM study,7 dihydroartemisinin–piperaquine was 
administered without first imposing a fast, providing 
further reassurance about safety. The results from this 
study are also consistent with the opinions of an expert 
panel convened by WHO to review the cardiotoxicity 
of antimalarial drugs,11 and with the conclusions of a 
meta-analysis reviewing the safety of repeated use of 
dihydroartemisinin–piperaquine.12 They further support 
the continued use of dihydroartemisinin–piperaquine in 
malaria-endemic areas.
Rigorous safety assessments of any new drug are 
necessary to safeguard patients. Generally, risk–benefit 
analyses of antimalarial drugs also need to account for 
the life-threatening potential and continuing morbidity 
associated with malaria. The findings from the WANECAM 
study support upscaling the use of pyronaridine–
artesunate and dihydroartemisinin–piperaquine in sub-
Saharan Africa so that they can contribute even more 
effectively to the global fight against malaria.
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